QR код

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

Abstract: Venetoclax is approved for older untreated acute myeloid leukemia (AML) patients. Venetoclax was available prior to approval off-label. We assessed our single-institution off-label experience with venetoclax/azacitidine, comparing outcomes with a clinical trial cohort that administered thi...

Повний опис

Збережено в:
Автори: Amanda C. Winters, Jonathan A. Gutman, Enkhtsetseg Purev, Molly Nakic, Jennifer Tobin, Stephanie Chase, Jeff Kaiser, Lindsey Lyle, Chelsey Boggs, Keri Halsema, Jeffrey T. Schowinsky, Julie Rosser, Mark D. Ewalt, Bradford Siegele, Vishal Rana, Steven Schuster, Diana Abbott, Brett M. Stevens, Craig T. Jordan, Clayton Smith, Daniel A. Pollyea
Формат: Artigo
Мова:Inglês
Опубліковано: Elsevier 2019-10-01
Серія:Blood Advances
Онлайн доступ:http://www.sciencedirect.com/science/article/pii/S2473952920318115
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси